Clinical trials: Dopamine
Idiopathic Parkinson's Disease
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons.
- Trial name
- MOTION (NCT01028586)
- Testing
- Safinamide, MAO-B inhibitor
- Where
- Switzerland
- Volunteers
- 507 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.
- Trial name
- NCT04588129
- Testing
- LB-102
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Diabetic Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
- Trial name
- NCT03544229
- Testing
- TAK-906 Maleate
- Where
- 109 sites in United States, Belgium and 2 more
- Volunteers
- 242 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lewy Body Dementia, Non-DLB Dementia
Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical…
- Conditions
- Lewy Body Dementia, Non-DLB Dementia, Alzheimer's, Vascular Dementia
- Trial name
- NCT00209456
- Testing
- DatSCAN
- Where
- Germany
- Volunteers
- 326 people
- Sponsor
- GE Healthcare
Parkinson Disease
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain.
- Trial name
- NCT07212088
- Testing
- ALC01 therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- iCamuno Biotherapeutics Ltd.
Parkinson's Disease
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
To determine the long-term safety and efficacy of a dose range of safinamide of 50-200 mg/day, p.o., compared to placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a…
- Trial name
- NCT00642889
- Testing
- Safinamide
- Volunteers
- 227 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson Disease
Phase 1/2a Study of ANPD001 in Parkinson Disease
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease.
- Trial name
- ASPIRO (NCT06344026)
- Testing
- ANPD001, Custom Device
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- Aspen Neuroscience
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
- Trial name
- NCT05654870
- Testing
- Valbenazine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Neurocrine Biosciences
Restless Legs Syndrome
Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation
This study evaluates Tonic Motor Activation (TOMAC) therapy in adults with restless legs syndrome and dopaminergic augmentation.
- Trial name
- CT-10 (NCT07397247)
- Testing
- Tonic Motor Activation (TOMAC) Device
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Noctrix Health, Inc.
Parkinson's Disease
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
The objective of this study is to assess the safety of VY-AADC02 in participants with Parkinson's disease (PD) with motor fluctuations.
- Trial name
- NCT03562494
- Testing
- VY-AADC02
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.
- Trial name
- TEAL (NCT04369430)
- Testing
- AKST4290
- Where
- 22 sites in United States, Estonia and 3 more
- Volunteers
- 110 people
- Sponsor
- Alkahest, Inc.
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide
The purpose of this study is: To assess the effect of BIA 5 1058 400 mg on furosemide pharmacokinetics (PK). To assess the effect of furosemide 40 mg on the PK of BIA 5 1058.
- Trial name
- NCT07173738
- Testing
- BIA 5-1058, Furosemide, BIA 5-1058 and Furosemide
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Idiopathic Parkinson's Disease
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the…
- Trial name
- SETTLE (NCT00627640)
- Testing
- Safinimide 50-100 mg/day
- Where
- 121 sites in United States, Australia and 19 more
- Volunteers
- 549 people
- Sponsor
- Newron Pharmaceuticals SPA
Healthy Men
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound
To investigate the relationship between the combined Lu AF35700 and Lu AF36152 plasma concentration and D2 dopamine receptor occupancy up to 172 hours after oral dosing of Lu AF35700
- Trial name
- NCT02093169
- Testing
- Part A: Lu AF35700, Part B: Lu AF35700
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy Volunteers
A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)
The purpose of this study is to determine brain penetration of single oral doses of TAK-041 and its effects on amphetamine-induced dopamine release in the Central Nervous System (CNS).
- Trial name
- NCT02959892
- Testing
- Amphetamine, TAK -041, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease
2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD
This study was designed to assess whether GPI 1485 has the ability to delay or stop disease progression and improve symptoms in patients with Parkinson's disease (PD) that is already being treated with a dopamine agonist therapy.
- Trial name
- NCT00209508
- Testing
- GPI 1485
- Volunteers
- 200 people
- Sponsor
- Eisai Inc.
Schizophrenia
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626859
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Tanabe Pharma Corporation
Parkinson's Disease, Motor Symptoms
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.
- Conditions
- Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility
- Trial name
- AM IMPAKT (NCT01770145)
- Testing
- APOKYN, L-dopa, Trimethobenzamide
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals